EMILY MCCOLLUM: Open Payments
NPI 1972270916 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$927 in 38 payments from 15 companies in 2025. Trend: 2023 $933 · 2024 $1,400 · 2025 $927
Food & beverage: $927
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $173 |
| Neurocrine BioSciences, Inc. | 5 | $153 |
| Janssen Scientific Affairs, LLC | 1 | $103 |
| ABBVIE INC. | 3 | $72 |
| Alkermes, Inc. | 3 | $69 |
| Lundbeck LLC | 3 | $62 |
| Tris Pharma Inc | 1 | $55 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| PFIZER INC. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
Products named: FANAPT, INGREZZA, SPRAVATO, VRAYLAR, REXULTI, Dyanavel XR, Auvelity, ELIQUIS.
Industry payments across CO — which companies pay providers there.
